Approved regulatory verdict
Evidence outlook
Approved: Acute Myeloid Leukemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development: Non-Small Cell Lung Cancer · Phase 1/2
How the evidence outlook works ↗
Featured trials The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Acute Myeloid Leukemia · approved · Featured evidence · 2 Non-Small Cell Lung Cancer · investigational · Reviewed, none selected approved Featured evidence · 2
Competitive landscape 125 competitors in this universe: 5 direct rivals (same mechanism and indication), 0 same-class, 120 same-indication.
Unlock with Research ↗ Drug Stage Modality Mechanism Evidence signal Reported efficacygraded featured trials Gilteritinib: this drug Approved Small molecule FLT3 Quizartinib Approved Small molecule FLT3 Clifutinib Besylate Phase 3 Small molecule FLT3 XY0206 Phase 3 Small molecule FLT3 Anti-CI135 CAR-T Phase 1 Cell therapy FLT3 BMF-500 Phase 1 — FLT3 Afatinib (Gilotrif)Approved Small molecule EGFR/HER1, HER2, HER4 Alectinib (Alecensa)Approved Small molecule ALK Alymsys (bevacizumab-Maly) Approved Monoclonal antibody VEGF-A Amivantamab Approved Multispecific antibody EGFR x c-MET ASTX727 Approved Small molecule Decitabine/cedazuridine fixed combination (DNMT + CDA inhibition) Atezolizumab Approved Monoclonal antibody PD-L1 BAT1706 (Avzivi)Approved Monoclonal antibody VEGF-A BAY2927088 (Hyrnuo)Approved Small molecule HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR Bevacizumab Approved Monoclonal antibody VEGF-A , Vascular Endothelial Growth Factor Inhibitor Bevacizumab-Awwb (MVASI)Approved Monoclonal antibody VEGF-A
…and 110 more. Research shows the complete landscape.
Research Unlock the full comparison Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Unlock with Research ↗ Upcoming events (32 total) Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (3) December 2026 (3) Phase 1 Acute Myeloid Leukemia Recruiting
Est. primary completion 2026-12 ·
NCT06001788 ·
CT.gov ↗ What to watch Phase 2 Acute Myeloid Leukemia Recruiting
Est. primary completion 2026-12 ·
NCT05955261 ·
CT.gov ↗ What to watch Phase 1 Acute Myeloid Leukemia Recruiting
Est. primary completion 2026-12-31 ·
NCT05010772 ·
CT.gov ↗ What to watch 2027 (8) January 2027 (1) Phase 1 Acute Myeloid Leukemia Recruiting
Est. primary completion 2027-01-31 ·
NCT06222580 ·
CT.gov ↗ What to watch February 2027 (1) Phase 1 Acute Myeloid Leukemia Recruiting
Est. primary completion 2027-02-15 ·
NCT05024552 ·
CT.gov ↗ What to watch April 2027 (1) Phase 1 Acute Myeloid Leukemia Recruiting
Est. primary completion 2027-04-21 ·
NCT05756777 ·
CT.gov ↗ What to watch May 2027 (2) Phase 1 Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Recruiting
Est. primary completion 2027-05 ·
NCT06225427 ·
CT.gov ↗ What to watch Phase 2 Acute Myeloid Leukemia Recruiting
Est. primary completion 2027-05-31 ·
NCT07548710 ·
CT.gov ↗ What to watch June 2027 (2) Phase 2 Targeted Therapy, IDH1-Mutated Malignancies, Mutations Recruiting
Est. primary completion 2027-06-01 ·
NCT07032727 ·
CT.gov ↗ What to watch Phase 1/2 Acute Myeloid Leukemia Recruiting
Est. primary completion 2027-06-30 ·
NCT04988555 ·
CT.gov ↗ What to watch October 2027 (1) Phase 1/2 Myeloid Leukemia Recruiting
Est. primary completion 2027-10-01 ·
NCT06235801 ·
CT.gov ↗ What to watch 2028 (12) January 2028 (2) Phase 1/2 Acute Myeloid Leukemia Recruiting
Est. primary completion 2028-01-30 ·
NCT05010122 ·
CT.gov ↗ What to watch Early phase / not applicable Acute Myeloid Leukemia Recruiting
Est. primary completion 2028-01-30 ·
NCT06265545 ·
CT.gov ↗ What to watch May 2028 (2) Early phase / not applicable Acute Myeloid Leukemia Recruiting
Est. primary completion 2028-05-10 ·
NCT07131059 ·
CT.gov ↗ What to watch Phase 3 Acute Myeloid Leukemia Recruiting
Est. primary completion 2028-05-31 ·
NCT07463651 ·
CT.gov ↗ What to watch July 2028 (2) Phase 2 Acute Myeloid Leukemia Active not recruiting
Est. primary completion 2028-07-10 ·
NCT05199051 ·
CT.gov ↗ What to watch Phase 1/2 Acute Myeloid Leukemia Active not recruiting
Est. primary completion 2028-07-31 ·
NCT05520567 ·
CT.gov ↗ What to watch August 2028 (2) Phase 2 Acute Myeloid Leukemia Not yet recruiting
Est. primary completion 2028-08 ·
NCT06667973 ·
CT.gov ↗ What to watch Early phase / not applicable Hematological Malignancies Not yet recruiting
Est. primary completion 2028-08 ·
NCT06992934 ·
CT.gov ↗ What to watch September 2028 (1) Phase 1/2 Acute Myeloid Leukemia Recruiting
Est. primary completion 2028-09-01 ·
NCT04140487 ·
CT.gov ↗ What to watch October 2028 (1) Phase 2/3 Acute Myeloid Leukemia Not yet recruiting
Est. primary completion 2028-10-01 ·
NCT07425808 ·
CT.gov ↗ What to watch December 2028 (2) Phase 2 Acute Myeloid Leukemia Recruiting
Est. primary completion 2028-12 ·
NCT06221683 ·
CT.gov ↗ What to watch Phase 2 Acute Myeloid Leukemia Recruiting
Est. primary completion 2028-12-31 ·
NCT07259707 ·
CT.gov ↗ What to watch 2029 (7) February 2029 (1) Phase 3 Acute Myeloid Leukemia Not yet recruiting
Est. primary completion 2029-02-01 ·
NCT07407140 ·
CT.gov ↗ What to watch April 2029 (1) Phase 2 Acute Myeloid Leukemia Recruiting
Est. primary completion 2029-04 ·
NCT06696183 ·
CT.gov ↗ What to watch May 2029 (2) Phase 2 Acute Myeloid Leukemia Recruiting
Est. primary completion 2029-05-15 ·
NCT06317649 ·
CT.gov ↗ What to watch Phase 2 Acute Myeloid Leukemia Recruiting
Est. primary completion 2029-05-15 ·
NCT05564390 ·
CT.gov ↗ What to watch June 2029 (1) Phase 3 Acute Myeloid Leukemia Recruiting
Est. primary completion 2029-06-30 ·
NCT04293562 ·
CT.gov ↗ What to watch October 2029 (1) Phase 2 Acute Myeloid Leukemia Not yet recruiting
Est. primary completion 2029-10-01 ·
NCT07755202 ·
CT.gov ↗ What to watch December 2029 (1) Phase 1 Non-Small Cell Lung Cancer Recruiting
Est. primary completion 2029-12-31 ·
NCT07140016 ·
CT.gov ↗ What to watch 2030 (1) May 2030 (1) Phase 2 Acute Myeloid Leukemia Recruiting
Est. primary completion 2030-05-31 ·
NCT02115295 ·
CT.gov ↗ What to watch 2032 (1) December 2032 (1) Phase 2/3 Acute Myeloid Leukemia Recruiting
Est. primary completion 2032-12 ·
NCT03013998 ·
CT.gov ↗ What to watch See the full readout calendar ↗
All registered studies Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.
All indications (61) Acute Myeloid Leukemia (52) Non-Small Cell Lung Cancer (3) Other / comorbidity (6)
Phase 3 (9) Phase 2/3 (2) Phase 2 (15) Phase 1/2 (14) Phase 1 (18) Early phase / not applicable (3)